Drug interactions
Empagliflozin-metformin + Erdafitinib
Severity: Moderate
Empagliflozin-metformin and Erdafitinib: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Erdafitinib may inhibit OCT2-mediated renal secretion, which could raise metformin concentrations. Higher metformin exposure increases the risk of gastrointestinal intolerance and, rarely, lactic acidosis. The legacy direction is unclear, but the clinically relevant effect is on metformin.
What this interaction means in plain words
Empagliflozin-metformin and Erdafitinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Empagliflozin-metformin belongs to Endocrine; Erdafitinib belongs to Oncology.
Why it happens
Inhibition of the renal transporter OCT2 reduces tubular secretion of metformin.
What to do
Monitor for metformin adverse effects, renal function and glycemic control. Reduce the metformin dose if intolerance develops.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Empagliflozin-metformin and Erdafitinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Empagliflozin-metformin
Other interactions of Erdafitinib
Frequently asked questions
Can I take Empagliflozin-metformin with Erdafitinib?
MediHelp rates the interaction as moderate. Empagliflozin-metformin and Erdafitinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Erdafitinib may inhibit OCT2-mediated renal secretion, which could raise metformin concentrations. Higher metformin exposure increases the risk of gastrointestinal intolerance and, rarely, lactic acidosis. The legacy direction is unclear, but the clinically relevant effect is on metformin.
How serious is the interaction between Empagliflozin-metformin and Erdafitinib?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for metformin adverse effects, renal function and glycemic control. Reduce the metformin dose if intolerance develops.
What other medicines interact with Empagliflozin-metformin?
MediHelp also lists interactions of Empagliflozin-metformin with, for example, Contrast media, Diatrizoate meglumine / diatrizoate, Diatrizoate. The full list is on the Empagliflozin-metformin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
